{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:45:09Z","timestamp":1792129509995,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.seminhematol.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:16:24Z","timestamp":1782918984000},"page":"103-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of myeloproliferative neoplasms in pregnancy: Essential thrombocythemia, polycythemia vera, and primary myelofibrosis"],"prefix":"10.1053","volume":"63","author":[{"given":"Kristen","family":"Corrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2026.06.005_bib0001","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0002","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0004","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.16453","article-title":"How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy","volume":"189","author":"Robinson","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0005","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/17474086.2018.1506325","article-title":"Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy","volume":"11","author":"Griesshammer","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4065\/76.1.22","article-title":"A long-term retrospective study of young women with essential thrombocythemia","volume":"76","author":"Tefferi","year":"2001","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.005_bib0007","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/s41375-022-01688-w","article-title":"Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms: a nationwide population-based study of 342 pregnancies in Sweden","volume":"36","author":"Landtblom","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0008","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0009","first-page":"1033","article-title":"NCCN guidelines insights: myeloproliferative neoplasms","volume":"20","author":"Mesa","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-2115(97)02734-6","article-title":"Coagulation and fibrinolysis changes in normal pregnancy: increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis","volume":"73","author":"Cerneca","year":"1997","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0011","first-page":"411","article-title":"Alterations in lower extremity venous hemodynamics associated with normal pregnancy","volume":"34","author":"Ballard","year":"2000","journal-title":"Vasc Endovascular Surg"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0012","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"Falanga","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.005_bib0013","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.005_bib0014","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0016","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0017","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia and polycythemia vera","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2257.1988.tb01190.x","article-title":"Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders","volume":"10","author":"Tatewaki","year":"1988","journal-title":"Clin Lab Haematol"},{"issue":"23","key":"10.1053\/j.seminhematol.2026.06.005_bib0019","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1182\/bloodadvances.2024013777","article-title":"Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis","volume":"8","author":"Venkat","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.06.005_bib0021","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F-positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.06.005_bib0022","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1084\/jem.20130295","article-title":"Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsia","volume":"211","author":"Cotechini","year":"2014","journal-title":"J Exp Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.005_bib0023","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.placenta.2010.12.005","article-title":"TNF-\u03b1 inhibits trophoblast integration into endothelial cellular networks","volume":"32","author":"Xu","year":"2011","journal-title":"Placenta"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.06.005_bib0024","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.humimm.2005.11.003","article-title":"Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia","volume":"66","author":"Gupta","year":"2005","journal-title":"Hum Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.005_bib0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 617V>F mutation","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.06.005_bib0026","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0609.2009.01214.x","article-title":"Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies","volume":"82","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0027","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ajh.21504","article-title":"Outcome of 122 pregnancies in essential thrombocythemia patients","volume":"84","author":"Melillo","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0028","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0029","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1055\/s-2003-44552","article-title":"Hyperviscosity in polycythemia vera and other red cell abnormalities","volume":"29","author":"Kwaan","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0030","first-page":"1477","article-title":"The management and outcome of 18 pregnancies in women with polycythemia vera","volume":"90","author":"Robinson","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0031","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.06.005_bib0032","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","article-title":"Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis","volume":"129","author":"Skeith","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.06.005_bib0033","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International prognostic Score of thrombosis in World Health Organization-essential thrombocythemia","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.06.005_bib0034","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.863612","article-title":"Venous thromboembolism risk score and pregnancy","volume":"9","author":"Raia-Barjat","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.06.005_bib0036","first-page":"143","article-title":"In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats","volume":"36","author":"Asano","year":"1987","journal-title":"Jikken Dobutsu"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0037","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/tera.1420070207","article-title":"Postnatal effects in rats of prenatal treatment with hydroxyurea","volume":"7","author":"Butcher","year":"1973","journal-title":"Teratology"},{"issue":"35","key":"10.1053\/j.seminhematol.2026.06.005_bib0038","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.06.005_bib0039","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12666","article-title":"Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis","volume":"2","author":"Maze","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106459","article-title":"Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia","volume":"98","author":"How","year":"2020","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2026.06.005_sbref0041","series-title":"Myeloproliferative Neoplasms Version 2","author":"National Comprehensive Cancer Network","year":"2022"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.06.005_bib0042","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.26067","article-title":"Myeloproliferative neoplasms and pregnancy: overview and practice recommendations","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106942","article-title":"Transfer of interferon beta in term placentae","volume":"107","author":"Doman","year":"2026","journal-title":"Mult Scler Relat Disord"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0044","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.reprotox.2011.11.003","article-title":"A systematic review of the fetal safety of interferon alpha","volume":"33","author":"Brojeni","year":"2012","journal-title":"Reprod Toxicol"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/frph.2021.702929","article-title":"Maternal and fetal outcomes after interferon exposure during pregnancy: a systematic review with meta-analysis","volume":"3","author":"Zhang","year":"2021","journal-title":"Front Reprod Health"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.06.005_bib0046","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/bloodadvances.2025018811","article-title":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant patients with MPN","volume":"10","author":"Tashi","year":"2026","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0047","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/AAP.0000000000000763","article-title":"Regional anesthesia in the patient receiving antithrombotic therapy","volume":"43","author":"Horlocker","year":"2018","journal-title":"Reg Anesth Pain Med"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0048","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.06.005_bib0049","series-title":"Peginterferon Alfa","year":"2006"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:58:32Z","timestamp":1792126712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0037196326000685"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.06.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of myeloproliferative neoplasms in pregnancy: Essential thrombocythemia, polycythemia vera, and primary myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}